WuHan Dong Kang Yuan Technology co., LTD

 

Integrity-based service-oriented Kangyuan products must be boutiques.

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsActive Pharmaceutical Ingredients

Agomelatine Active Pharmaceutical Ingredients 138112-76-2 For Treat Depression

Agomelatine Active Pharmaceutical Ingredients 138112-76-2 For Treat Depression

Agomelatine Active Pharmaceutical Ingredients 138112-76-2 For Treat Depression
Agomelatine Active Pharmaceutical Ingredients 138112-76-2 For Treat Depression

Large Image :  Agomelatine Active Pharmaceutical Ingredients 138112-76-2 For Treat Depression Get Best Price

Product Details:

Place of Origin: China
Brand Name: DKY
Model Number: 138112-76-2

Payment & Shipping Terms:

Minimum Order Quantity: 10g
Packaging Details: 1kg/bag or 25kg/drum
Delivery Time: 5-7 work days
Payment Terms: T/T, Western Union, MoneyGram
Supply Ability: 800 kgs per year
Detailed Product Description
CAS: 138112-76-2 Molecular Formula: C15H17NO2
Molecular Weight: 243.301 Appearance: White To Almost White Powder To Crystal
Melting Point: 107-109 ° C Purity(HPLC): Min. 98.0 Area%
Boiling Point: 478.8±28.0°C At 760 MmHg Storage Temperature: 0-10°C
High Light:

active pharma ingredients

,

pharmaceutical grade api intermediate

Agomelatine 138112-76-2 Active Pharmaceutical Ingredients to treat depression

 

Basic parameter:

1. Product name: agomelatine

2. Chemical name: N-[2-(7-methoxynaphthalene - 1-group) ethyl] acetamide

3. CAS: 138112-76-2

4. Molecular formula: C15H17NO2

5. Molecular weight: 243.301

6. Appearance: white or white-like crystalline powder.

7. Melting point: 107-109 ° C

8. Appearance: White to Almost White powder to crystal

9. Purity(HPLC) : min. 98.0 area%

10. Melting point: 108.0 to 112.0 deg-c

11. Boiling point: 478.8±28.0°C at 760 mmHg

12. Purity/analysis method: >98.0%(HPLC)(N)

13. Storage temperature: 0-10°C

 

Certificate of Analysis:

Product name

Agomelatine

Batch no

20200122

CAS

138112-76-2

Mfg. date

20200122

Test date

20200122

Testing item

Specification

Result

Appearance

A white powder

A white powder

Assay(HPLC)

≥99%

99.76%

Melting point

106-111

Complies

Residue

<0.1%

0.064%

Loss on drying

<0.5%

0.37%

Total impurity

<0.5%

0.24%

Result

Qualified

 

Structure:
Agomelatine Active Pharmaceutical Ingredients 138112-76-2 For Treat Depression 0
 
 
Pharmacological toxicology:
Agomelatine is a melatonin receptor agonist (MT1 and MT2 receptors) and a 5-ht2c receptor antagonist. Animal studies have shown that agomelatine can correct the circadian rhythm in animal models of circadian rhythm disorder, enabling the rhythm to be reconstructed. Agomelatine has shown antidepressant effects in a variety of animal models of depression. The mechanism of antidepressant may be related to the increased plasticity and proliferation of neurons in the hippocampus. Immunostaining was used to measure the proliferation, regeneration and death of nerve cells in the brain of adult rats. It was found that long-term (3 weeks) administration of agomelatine increased the proliferation of cells and neuron regeneration in the ventral dentate gyrus of the hippocampus, which is associated with emotional response. However, no similar condition was observed at the time of acute or subacute administration (4 hours or 9 weeks). After prolonged administration, cell proliferation and neuron regeneration occurred in the whole dentate gyrus region, indicating that agomelatine can increase the nerve regeneration in hippocampus to different degrees, thus producing new granulosa cells.
 
Patients with depression often have difficulty falling asleep, waking early or changing sleep rhythm. Polysomnography is often shown as decreased slow-wave sleep (SWS), increased REM density or decreased latency, and decreased delta sleep ratio, etc. Most antidepressants, such as tricyclic antidepressants (TCA) and selective 5-ht reuptake inhibitors (SSRI), have a regulating effect on REM, but have a poor effect on non-rem sleep, especially on SWS. Some drugs with the blocking effect of 5-ht2 receptor, such as mianserine and mianserine, have the effect of promoting sleep and improving sleep continuity, but the blocking effect can cause sleepiness and daytime sleepiness. Agomelatine has a unique pharmacological mechanism that regulates the sleep wake cycle, so it can regulate the sleep structure of patients at night and promote sleep.
 
I am Angela
Contact Angela, you would never regret.
email: zs@dkybpc.com
Tel: +86-15377658509, you can add me on WeChat or Skype or Whatsapp if you are using that.
 

Contact Details
WuHan Dong Kang Yuan technology co., LTD

Contact Person: Angela

Tel: 86-15377658509

Send your inquiry directly to us